deutetrabenazine for the treatment of chorea associated with Huntington’s disease
This is a comprehensive review of the literature regarding the use of Deutetrabenazine in treating chorea associated with Huntington’s disease. Unfortunately, treatment has been limited for many aspects of this neurodegenerative disease. The present investigation presents the background, evidence, a...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Open Medical Publishing
2022-06-01
|
| Series: | Health Psychology Research |
| Online Access: | https://doi.org/10.52965/001c.36040 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1825139344197812224 |
|---|---|
| author | Harshit Gupta Wil Perkins Cain Stark Sathya Kikkeri Juyeon Kakazu Adam D. Kaye Alan D. Kaye |
| author_facet | Harshit Gupta Wil Perkins Cain Stark Sathya Kikkeri Juyeon Kakazu Adam D. Kaye Alan D. Kaye |
| author_sort | Harshit Gupta |
| collection | DOAJ |
| description | This is a comprehensive review of the literature regarding the use of Deutetrabenazine in treating chorea associated with Huntington’s disease. Unfortunately, treatment has been limited for many aspects of this neurodegenerative disease. The present investigation presents the background, evidence, and indications for the use Deutetrabenazine in the setting of Huntington’s disease. Huntington’s disease is characterized by a variety of motor, psychiatric, and cognitive symptoms with chorea being one of the more notable ones. Chorea is a movement disorder present in multiple neurologic diseases that causes involuntary and irregular muscle movements theorized to be stemming from high dopamine levels. Deutetrabenazine is thought to function as an inhibitor of the VMAT2 vesicular monoamine transporter resulting in decreased monoamine release, including dopamine, in the synaptic cleft which has a therapeutic effect in management of chorea. This drug was approved by the FDA in 2017 with a specific indication for tardive dyskinesia and choreiform movement in Huntington’s disease. Currently, there is no definitive treatment for Huntington’s disease. Thus, management is primarily focused on symptom management with the use of a variety of pharmaceutical agents. Chorea is one of the many manifestations that significantly alter the quality of life of many patients. Deutetrabenazine is a promising new option for the treatment of chorea in the setting of Huntington’s disease. Although studies so far have displayed mixed results, further research, including head-to-head studies, is necessary to elucidate the true potential of this drug. |
| format | Article |
| id | doaj-art-af10e5bd1d9b4b2e97d43b69099aa4e0 |
| institution | Kabale University |
| issn | 2420-8124 |
| language | English |
| publishDate | 2022-06-01 |
| publisher | Open Medical Publishing |
| record_format | Article |
| series | Health Psychology Research |
| spelling | doaj-art-af10e5bd1d9b4b2e97d43b69099aa4e02025-02-11T20:30:36ZengOpen Medical PublishingHealth Psychology Research2420-81242022-06-01105deutetrabenazine for the treatment of chorea associated with Huntington’s diseaseHarshit GuptaWil PerkinsCain StarkSathya KikkeriJuyeon KakazuAdam D. KayeAlan D. KayeThis is a comprehensive review of the literature regarding the use of Deutetrabenazine in treating chorea associated with Huntington’s disease. Unfortunately, treatment has been limited for many aspects of this neurodegenerative disease. The present investigation presents the background, evidence, and indications for the use Deutetrabenazine in the setting of Huntington’s disease. Huntington’s disease is characterized by a variety of motor, psychiatric, and cognitive symptoms with chorea being one of the more notable ones. Chorea is a movement disorder present in multiple neurologic diseases that causes involuntary and irregular muscle movements theorized to be stemming from high dopamine levels. Deutetrabenazine is thought to function as an inhibitor of the VMAT2 vesicular monoamine transporter resulting in decreased monoamine release, including dopamine, in the synaptic cleft which has a therapeutic effect in management of chorea. This drug was approved by the FDA in 2017 with a specific indication for tardive dyskinesia and choreiform movement in Huntington’s disease. Currently, there is no definitive treatment for Huntington’s disease. Thus, management is primarily focused on symptom management with the use of a variety of pharmaceutical agents. Chorea is one of the many manifestations that significantly alter the quality of life of many patients. Deutetrabenazine is a promising new option for the treatment of chorea in the setting of Huntington’s disease. Although studies so far have displayed mixed results, further research, including head-to-head studies, is necessary to elucidate the true potential of this drug.https://doi.org/10.52965/001c.36040 |
| spellingShingle | Harshit Gupta Wil Perkins Cain Stark Sathya Kikkeri Juyeon Kakazu Adam D. Kaye Alan D. Kaye deutetrabenazine for the treatment of chorea associated with Huntington’s disease Health Psychology Research |
| title | deutetrabenazine for the treatment of chorea associated with Huntington’s disease |
| title_full | deutetrabenazine for the treatment of chorea associated with Huntington’s disease |
| title_fullStr | deutetrabenazine for the treatment of chorea associated with Huntington’s disease |
| title_full_unstemmed | deutetrabenazine for the treatment of chorea associated with Huntington’s disease |
| title_short | deutetrabenazine for the treatment of chorea associated with Huntington’s disease |
| title_sort | deutetrabenazine for the treatment of chorea associated with huntington s disease |
| url | https://doi.org/10.52965/001c.36040 |
| work_keys_str_mv | AT harshitgupta deutetrabenazineforthetreatmentofchoreaassociatedwithhuntingtonsdisease AT wilperkins deutetrabenazineforthetreatmentofchoreaassociatedwithhuntingtonsdisease AT cainstark deutetrabenazineforthetreatmentofchoreaassociatedwithhuntingtonsdisease AT sathyakikkeri deutetrabenazineforthetreatmentofchoreaassociatedwithhuntingtonsdisease AT juyeonkakazu deutetrabenazineforthetreatmentofchoreaassociatedwithhuntingtonsdisease AT adamdkaye deutetrabenazineforthetreatmentofchoreaassociatedwithhuntingtonsdisease AT alandkaye deutetrabenazineforthetreatmentofchoreaassociatedwithhuntingtonsdisease |